18F-Florbetaben을 이용한 대조군과 기억성 경도인지장애 및 알츠하이머병 환자군의 아밀로이드 침착 패턴 양상 : 복셀 기반 영상분석
A Voxel Wise Analysis of Cerebral Beta Amyloid Retention in Healthy Controls and Subjects with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective：The purpose of the study was to compare cortical amyloid deposition using 18F-florbetaben and positron emission tomography (PET) in healthy controls and subjects with amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD). Methods：We investigated 25 patients : 10 age-matched healthy controls, 10 patients with aMCI and 5 with AD. All participants underwent PET after intravenous injection of 300 MBq of 18F-florbetaben. The 90 min post-injection brain PET data were analysed using statistical parametric mapping. Results：When compared to healthy controls, amyloid deposition was significantly higher in frontal lobe medial frontal gyrus, limbic lobe posterior cingulate, parietal lobe precuneus, sub-loba insula, temporal lobe superior temporal gyrus, parietal lobe inferior parietal lobule, temporal lobe middle temporal gyrus, parietal lobe supramarginal gyrus, occipital lobe middle temporal gyrus of patient group (family wise error correction p<0.05). Conclusion：These results indicate 18F-florbetaben to be an efficacious β-amyloid-targeted tracer. Subjects with aMCI, AD could be easily differentiated from healthy controls by assessment of the PET data.
Abstract
Objective：The purpose of the study was to compare cortical amyloid deposition using 18F-florbetaben and positron emission tomography (PET) in healthy controls and subjects with amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD). Methods：We investigated 25 patients : 10 age-matched healthy controls, 10 patients with aMCI and 5 with AD. All participants underwent PET after intravenous injection of 300 MBq of 18F-florbetaben. The 90 min post-injection brain PET data were analysed using statistical parametric mapping. Results：When compared to healthy controls, amyloid deposition was significantly higher in frontal lobe medial frontal gyrus, limbic lobe posterior cingulate, parietal lobe precuneus, sub-loba insula, temporal lobe superior temporal gyrus, parietal lobe inferior parietal lobule, temporal lobe middle temporal gyrus, parietal lobe supramarginal gyrus, occipital lobe middle temporal gyrus of patient group (family wise error correction p<0.05). Conclusion：These results indicate 18F-florbetaben to be an efficacious β-amyloid-targeted tracer. Subjects with aMCI, AD could be easily differentiated from healthy controls by assessment of the PET data.
참고문헌 (23)
- Suk SH, "Usefulness of occipital EEG spectral profile in the differential diagnosis of Alzheimer type and vascular dementia", J Korean Neurol Assoc, 18, pp.292~297 (2000)
- Banerjee S, "Clinical and cost effectiveness of services for early diagnosis and intervention in dementia", Int J Geriatr Psychiatry, 24, pp.748~754 (2009)
- Richards D, "Florbetaben for PET imaging of betaamyloid plaques in the brain", Neurol Ther, 3, pp.79~88 (2014)
- AV-45 positron emission tomography in Chinese population, "PLoS One", 2013, e58974~
- McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
- Weiner MF, "Alzheimer's disease: diagnosis and treatment", Harv Rev Psychiatry, 4, pp.306~316 (1997)
- Sperling RA, "Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.280~292 (2011)
- O’Brien JT, "Amyloid imaging for dementia in clinical practice", BMC Med, 13, pp.163~ (2015)
- 김재승, "퇴행성 뇌질환에서의 분자영상", 대한의사협회지, 52(2), pp.151~167 (2009), 대한의사협회
- 정재민, "베타아밀로이드 영상용 프로브", Nuclear Medicine and Molecular Imaging, 41(2), pp.112~117 (2007), 대한핵의학회
- Rowe CC, "Imaging of amyloid beta in Alzheimer’s disease with 18FBAY94-9172, a novel PET tracer: proof of mechanism", Lancet Neurol, 7, pp.129~135 (2008)
- Zhang W, "F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain", Nucl Med Biol, 32, pp.799~809 (2005)
- Barthel H, "Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study", Lancet Neurol, 10, pp.424~435 (2011)
- Ong KT, "Aβ imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study", J Neurol Neurosurg Psychiatry, 86, pp.431~436 (2015)
- Villemagne VL, "Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease", Eur J Nucl Med Mol Imaging, 39, pp.983~989 (2012)
- Sabri O, "Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study", Alzheimers Dement, 11, pp.964~974 (2015)
- Hughes CP, "A new clinical scale for the staging of dementia", Br J Psychiatry, 140, pp.566~572 (1982)
- Kukull WA, "The validity of 3 clinical diagnostic criteria for Alzheimer’s disease", Neurology, 40, pp.1364~1369 (1990)
- Petersen RC, "Mild cognitive impairment: clinical characterization and outcome", Arch Neurol, 56, pp.303~308 (1999)
- Barthel H, "Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls", Eur J Nucl Med Mol Imaging, 38, pp.1702~1714 (2011)
- Klunk WE, "Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B", Ann Neurol, 55, pp.306~319 (2004)
- Forsberg A, "PET imaging of amyloid deposition in patients with mild cognitive impairment", Neurobiol Aging, 29, pp.1456~1465 (2008)
- Okello A, "Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study", Neurology, 73, pp.754~760 (2009)